Anaplerotic Reactions and Cycle Regulation

Anaplerotic control is now a direct clinical and pharmacological target. In inherited metabolic disease, pyruvate carboxylase deficiency causes a severe, often fatal, form of lactic acidosis with hypoglycemia and neurological impairment, precisely because the cycle stalls and gluconeogenesis fails simultaneously — a direct clinical confirmation of the mass-balance argument developed above. Propionic acidemia and methylmalonic acidemia, defects in the anaplerotic propionyl-CoA-to-succinyl-CoA pathway, cause toxic accumulation of propionyl-CoA and its derivatives, illustrating that anaplerotic pathways are not merely convenient shortcuts but essential detoxification routes for odd-chain and branched-chain carbon skeletons. In cancer metabolism, many tumors exhibit "glutamine addiction" — using glutaminolysis (glutamine → glutamate → α-ketoglutarate via glutaminase and glutamate dehydrogenase or transamination) as a major anaplerotic route to refill the cycle, because rapid proliferation drains citrate for lipogenesis and OAA for nucleotide and amino acid synthesis far faster than glucose-derived pyruvate carboxylase flux alone can replace it. This has made glutaminase inhibitors (such as CB-839/telaglenastat) an active area of oncology drug development, explicitly targeting anaplerotic flux to starve tumor biosynthesis. In exercise physiology and sports science, anaplerotic flux through pyruvate carboxylase and via alanine/glutamate transamination in skeletal muscle is measured (using isotopic tracers and NMR-based flux analysis) to understand how muscle sustains high oxidative rates during endurance exercise, and dietary strategies (e.g., branched-chain amino acid or triheptanoin/odd-chain fat supplementation feeding the propionyl-CoA route) are actively studied as ways to support anaplerosis in patients with certain fatty acid oxidation and cycle-related disorders. In industrial biotechnology, engineered E. coli and yeast strains overexpress or rebalance PEP carboxylase and pyruvate carboxylase to redirect carbon flux for overproduction of amino acids (e.g., glutamate, lysine) and organic acids (succinate, malate) — a direct industrial application of tuning anaplerotic/cataplerotic balance for metabolic engineering.

Ask the tutor: How do the anaplerotic and cataplerotic fluxes described here get integrated with hormonal signals like insulin and glucagon at the whole-body level?

Picture the citric acid cycle not as a wheel with a fixed amount of material circulating forever, but as a rotating loading dock. Acetyl-CoA arrives at citrate synthase and condenses with oxaloacetate (OAA) to form citrate. As citrate proceeds through isocitrate, α-ketoglutarate, succinyl-CoA, succinate, fumarate, and malate, it is finally reoxidized back to OAA. In a cell that only burns fuel to CO₂ and never diverts any intermediate for biosynthesis, this loop is perfectly catalytic — the total carbon in the cycle pool (OAA + citrate + isocitrate + α-KG + succinyl-CoA + succinate + fumarate + malate) stays constant, and only the two carbons of the incoming acetyl group are oxidized and released as two CO₂ per turn. But that idealization is not how cells actually use the cycle. α-Ketoglutarate is pulled off to make glutamate and, downstream, other amino acids and neurotransmitters. Succinyl-CoA is pulled off to make heme. Citrate is exported to the cytosol as the carbon source for fatty acid synthesis. Oxaloacetate itself is drawn off for gluconeogenesis via phosphoenolpyruvate carboxykinase. Every one of these withdrawals is cataplerotic — it removes a four-, five-, or six-carbon skeleton from the loop. If nothing replaced that carbon, the pool would shrink, oxaloacetate concentration would fall, citrate synthase (whose Kₘ for OAA is in the low micromolar range, comparable to typical mitochondrial OAA concentrations) would slow, and the whole cycle would stall — not because acetyl-CoA delivery failed, but because there is no acceptor to receive it. Anaplerotic reactions are the topping-up mechanisms. The dominant one in most tissues is pyruvate carboxylase, which carboxylates pyruvate to oxaloacetate directly, spending one ATP and consuming bicarbonate. In liver and kidney, phosphoenolpyruvate carboxykinase can also run "backward" relative to its gluconeogenic direction to fix CO₂ into OAA when needed, though this is a minor pathway compared to pyruvate carboxylase under most physiological conditions. Transamination reactions feed glutamate's carbon skeleton back in as α-ketoglutarate. And the propionyl-CoA pathway, fed by odd-chain fatty acid oxidation and by the branched-chain amino acids valine and isoleucine, carboxylates propionyl-CoA to methylmalonyl-CoA and then isomerizes it to succinyl-CoA. Regulation of the cycle's throughput — as opposed to the size of its intermediate pool — is a separate problem, governed by the enzymes at citrate synthase, isocitrate dehydrogenase, and α-ketoglutarate dehydrogenase, which sense ATP/ADP and NADH/NAD⁺ ratios and, in muscle, Ca²⁺ released during contraction.

The steady-state size of the cycle's intermediate pool is set by a flux balance between carbon entering anaplerotically and carbon leaving cataplerotically:

where:

• $[\text{pool}]$ is the total concentration of cycle intermediates (OAA + citrate + isocitrate + α-KG + succinyl-CoA + succinate + fumarate + malate), roughly conserved in carbon-skeleton terms since they interconvert without net carbon loss except at the two decarboxylation steps
• $v_{\text{anaplerotic}}$ is the sum of fluxes through pyruvate carboxylase, PEP carboxykinase (carboxylating direction), glutamate dehydrogenase/transaminases feeding α-KG, and propionyl-CoA carboxylase feeding succinyl-CoA
• $v_{\text{cataplerotic}}$ is the sum of fluxes drained for gluconeogenesis (OAA→PEP), lipogenesis (citrate→cytosol), amino acid and heme synthesis (α-KG, succinyl-CoA), and other biosynthetic branch points

At steady state $d[\text{pool}]/dt = 0$: anaplerosis must exactly match cataplerosis, or the pool drifts and cycle turnover (a separate, much faster quantity) changes with it. Turnover rate of the cycle itself — how many times per second acetyl-CoA is oxidized — is governed by mass-action-corrected rate expressions at the three control points, each responsive to the energy charge,

where:

• $EC$ ranges from 0 (all AMP) to 1 (all ATP)
• typical resting cytosolic/mitochondrial $EC$ in most cells is 0.80–0.95
• a drop in $EC$ of even a few percent produces a large relative rise in ADP and AMP (because ATP is present in vast excess over ADP/AMP at rest), and it is this ADP/AMP signal, not ATP directly, that activates isocitrate dehydrogenase and, indirectly, the whole cycle

and to the redox state, expressed as the ratio

where a high $R$ (electron transport chain backed up, e.g., during hypoxia or high substrate load without ADP to phosphorylate) allosterically and mass-action-inhibits isocitrate dehydrogenase and α-ketoglutarate dehydrogenase, and directly reverses malate dehydrogenase's equilibrium. The thermodynamic core of the "malate dehydrogenase paradox" — a highly unfavorable standard-state reaction that nonetheless runs forward in vivo — is captured by the actual free energy expression:

where:

• $\Delta G^{\circ\prime}_{\text{MDH}} \approx +29.7\ \text{kJ/mol}$ (strongly unfavorable at standard conditions)
• $[\text{OAA}]$ is kept extremely low (sub-micromolar to low micromolar) because citrate synthase consumes it essentially as fast as it is made and has a very low $K_m$ for OAA (~1–4 μM)
• driving $[\text{OAA}]$ down by several orders of magnitude relative to $[\text{malate}]$ makes the reaction quotient term strongly negative, dragging $\Delta G$ below zero despite the unfavorable standard value

Example 1 — Foundational: ATP cost of replenishing oxaloacetate via pyruvate carboxylase versus the cost of losing a turn of the cycle. Pyruvate carboxylase catalyzes

This costs one ATP-equivalent (ATP → ADP + Pi, not ATP → AMP + PPi, so it is a single high-energy bond cleaved) per oxaloacetate made. Compare this to the ATP-equivalent value the cell would lose if the cycle stalled for want of OAA: one full turn of the citric acid cycle nets 3 NADH (≈3 × 2.5 = 7.5 ATP by oxidative phosphorylation, using the commonly used P/O ratio of ~2.5 for NADH), 1 FADH₂ (≈1.5 ATP), and 1 GTP directly, totaling roughly

Spending 1 ATP on pyruvate carboxylase to keep the cycle turning and thereby capture ~10 ATP-equivalents per turn is an excellent energetic trade — anaplerosis is "expensive" only in the sense of consuming ATP directly, but it protects a much larger downstream energetic yield, which is why the cell tolerates the cost even under energy-limited conditions, provided pyruvate and CO₂ are available.

Example 2 — Applied: regulation during the fed-to-fasted transition in liver. Immediately after a carbohydrate meal, liver cytosolic acetyl-CoA and citrate are elevated (citrate is exported for fatty acid synthesis), which is cataplerotic. Insulin signaling favors glycolysis and suppresses gluconeogenesis, so PEP carboxykinase flux (a competing cataplerotic drain on OAA) is low. Pyruvate carboxylase flux, however, is stimulated because acetyl-CoA (from excess pyruvate via pyruvate dehydrogenase, itself favored when insulin dephosphorylates and activates PDH) is a potent allosteric activator of pyruvate carboxylase. Concretely: acetyl-CoA binds an allosteric site on pyruvate carboxylase and increases its affinity for pyruvate/bicarbonate and its $V_{max}$, with reported activation providing several-fold increases in activity as acetyl-CoA rises from near-zero toward saturating (~10–20 μM range in liver mitochondria). This is the feed-forward loop referenced earlier: high acetyl-CoA signals "there is plenty of fuel entering; make sure OAA is available to receive it," which both permits high citrate synthase flux (feeding fatty acid synthesis via citrate export) and replenishes the OAA consumed by that export. During prolonged fasting, the signaling flips: glucagon-driven phosphorylation activates PEP carboxykinase gene expression and gluconeogenic flux rises sharply — now OAA is drained toward glucose rather than being retained for the cycle. Pyruvate carboxylase flux stays high (fatty-acid-derived acetyl-CoA from adipose lipolysis keeps it activated), but nearly all of the OAA made is immediately cataplerotically diverted to PEP rather than condensing with acetyl-CoA. The cycle itself in liver during fasting shifts toward being a "gluconeogenic support pathway" rather than a purely oxidative one, illustrating that anaplerosis and cataplerosis are both high simultaneously, not mutually exclusive — the balance, not the absolute level of either flux, determines whether net intermediates accumulate.

Example 3 — Exam/competition level: computing the shift in isocitrate dehydrogenase flux from a change in ADP and NADH during the rest-to-exercise transition. Isocitrate dehydrogenase (IDH, the NAD⁺-dependent mitochondrial isoform) is allosterically activated by ADP and Ca²⁺ and inhibited by ATP and NADH. A simplified but quantitatively useful empirical rate law (of the type used in classic kinetic studies of bovine heart IDH) treats ADP as a K-type activator that lowers the apparent $K_m$ for isocitrate, giving approximately

where $K_m^0$ is the (high) Michaelis constant in the absence of ADP, and $K_i$ is the ADP activation constant. Suppose at rest: $[\text{ADP}] = 15\ \mu M$, $K_i = 25\ \mu M$, $K_m^0 = 400\ \mu M$, and $[\text{isocitrate}] = 60\ \mu M$ (below-saturating, physiologically realistic).

During intense exercise, ADP rises roughly tenfold in contracting muscle mitochondria as ATP is hydrolyzed for contraction faster than oxidative phosphorylation initially replaces it: take $[\text{ADP}] = 150\ \mu M$, with isocitrate rising somewhat too (say to 90 μM as flux through the earlier steps increases):

The fold-activation is

A roughly threefold rise in ADP-driven, isocitrate-assisted flux through IDH — well before any change in enzyme amount — illustrates how allosteric control alone can triple oxidative flux within seconds of the onset of exercise, matching the near-instantaneous rise in oxygen consumption seen physiologically. Limiting case: as $[\text{ADP}] \to 0$, $K_m^{\text{app}} \to K_m^0 = 400\ \mu M$, recovering the low, ADP-unstimulated basal rate; as $[\text{ADP}] \to \infty$, $K_m^{\text{app}} \to 0$ and $v \to V_{max}$, the fully activated ceiling, showing the model saturates sensibly rather than diverging.

Anaplerosis as a formal concept was named and systematically analyzed by Harland G. Wood and, independently in naming the phenomenon, by the biochemist Harold A. Krebs collaborating with his contemporaries studying carbon dioxide fixation in animal tissues in the 1930s–1940s. The crucial experimental discovery — that animal tissues can fix CO₂ into four-carbon dicarboxylic acids, not just plants and bacteria — came from work by Harland Wood and Chester Werkman in the early 1930s on bacterial CO₂ fixation (the "Wood–Werkman reaction," propionic acid bacteria fixing CO₂ into succinate), which reframed CO₂ fixation as a general biochemical capability rather than a plant-exclusive process. This insight fed directly into the mammalian biochemistry that followed: once Krebs had established the cyclic pathway itself, the question of how its intermediates were replenished against continuous biosynthetic withdrawal became pressing, and it was in this context that the term "anaplerotic" (from the Greek ana- "up" and plerotikos "to fill") was coined and popularized, notably associated with the biochemist H. L. Kornberg, who in the 1960s formalized the anaplerotic/cataplerotic framework while studying the glyoxylate cycle and bacterial central metabolism.